Vaxart and Westwood & Wilshire Partner to Hire Chief Financial Officer
December 19, 2022, South San Francisco, CA - Vaxart, a clinical-stage public biotechnology company, has brought on Phillip Lee as Chief Financial Officer. Vaxart is developing a range of oral vaccines based on its proprietary delivery platform. These which could dramatically improve patient acceptance, reduce supply chain costs, and increase vaccination rates globally. Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.
Phil brings extensive strategic finance and advisory experience, starting in investment banking at Merrill Lynch and Centerview Partners where he held the role as Principal, and was a founding member of Centerview’s healthcare advisory practice. He joins Vaxart from his role as CFO and COO with Clover Biopharmaceuticals, where he raised the Series C funding and took the company public on HKEX. Prior to Clover he held finance leadership positions at 4D Molecular Therapeutics, Cytokinetics, and Avalanche Biotechnologies.
The search was led successfully by Andrea Tegstam.
About Westwood & Wilshire
Westwood & Wilshire is a retained executive-search firm delivering premier talent in life sciences, healthcare and advanced technology to the world’s most innovative companies. Our specialty is bringing top-flight senior leadership to growing venture-backed companies looking for the best people to fill their C-Suite hires. Clients around the globe work with Westwood & Wilshire to build world-changing companies. Contact information can be found at https://westwoodwilshire.com/contact-us.
